Tau antisense oligonucleotide (ASO) therapy represents a gene-silencing approach for treating Alzheimer's disease and other tauopathies. Unlike antibody-based immunotherapies that clear tau after it's produced, ASOs prevent tau production at the source by degrading MAPT messenger RNA (mRNA). This approach offers a fundamentally different mechanism with potential for disease modification.
Tau ASO therapy works through RNA interference at the molecular level:
¶ 1. ASO Design and Target Selection
- Target: MAPT mRNA (the messenger RNA encoding the tau protein)
- Sequence: ASO is designed to be complementary to a specific region of MAPT mRNA
- Chemistry: Modified ASOs with phosphorothioate backbone for enhanced stability and CNS delivery
Once the ASO binds to its target mRNA:
- Hybrid Formation: ASO forms a duplex with target mRNA
- RNase H1 Recruitment: The DNA-RNA hybrid recruits RNase H1 enzyme
- mRNA Cleavage: RNase H1 cleaves the RNA strand within the hybrid
- Degradation: The cleaved mRNA fragments are degraded by cellular exonucleases
- Translation Block: Without intact mRNA, ribosomes cannot produce tau protein
The result is a coordinated reduction in:
- Total Tau: All tau isoforms produced from MAPT gene
- Phospho-tau: Pathologically phosphorylated tau species
- Tau Aggregates: Reduced substrate for aggregate formation
- Tau Spread: Lower levels available for propagation
The most advanced tau ASO, BIIB080 (developed by Biogen and Ionis), has demonstrated compelling results:
Phase I Trial (NCT03119818):
- Dose-dependent reduction in CSF total tau (up to 50-60%)
- Dose-dependent reduction in CSF phospho-tau species
- Acceptable safety profile
- Results published in Nature Medicine (2022)
Phase I/II Trial (NCT04784160):
- Sustained tau reduction over extended treatment
- Validated the ASO approach in AD patients
- Results published in JAMA Neurology (2023)
Phase II Trial (NCT05399888):
- Active for early Alzheimer's disease
- Further evaluation of cognitive endpoints
NIO752 is another tau ASO developed by Roche/Ionis for PSP and AD:
- Target: MAPT mRNA
- Results: Demonstrated target engagement in Phase I
- Status: Phase I completed for PSP
¶ Advantages Over Antibody Therapy
Tau ASO therapy offers several potential advantages:
| Feature |
ASO Therapy |
Antibody Therapy |
| Mechanism |
Prevents tau production |
Clears existing tau |
| Target |
mRNA (source) |
Protein (product) |
| Distribution |
CNS-wide after intrathecal |
Limited by BBB |
| Isoform Coverage |
All isoforms |
Depends on epitope |
| Dosing Frequency |
Monthly to quarterly |
Monthly |
ASOs address the root cause of tau pathology:
- Prevention: Stops new tau production before aggregates form
- Reduction: Lowers overall tau burden
- Combination Potential: Could be combined with amyloid clears
¶ Challenges and Limitations
- Intrathecal Administration: Requires lumbar puncture for CNS delivery
- Distribution: May not reach all brain regions uniformly
- Patient Burden: More invasive than intravenous antibody infusion
- Off-Target Effects: ASOs may affect unintended RNAs
- Long-Term Safety: Unknown effects of chronic tau reduction
- Target Engagement: Requires demonstration of CSF tau lowering
- Patient Selection: Optimal patient population unclear
- Biomarker Correlation: CSF tau reduction may not predict clinical benefit
- Trial Design: Long trials needed for disease modification endpoints
| Drug |
Company |
Target |
Phase |
Key Results |
| BIIB080 |
Biogen/Ionis |
MAPT mRNA |
Phase II |
50-60% CSF tau reduction |
| NIO752 |
Roche/Ionis |
MAPT mRNA |
Phase I |
Target engagement demonstrated |
| ARO-MAPT |
Arrowhead |
MAPT mRNA (RNAi) |
Preclinical |
Preclinical proof-of-concept |
Tau ASO therapy continues to evolve:
- Improved Delivery: Exploring convection-enhanced delivery and AAV vectors
- Oral ASOs: Next-generation ASOs with oral bioavailability
- Combination Therapy: ASO + amyloid antibody combinations
- Biomarker Integration: Using plasma p-tau for patient selection
- Gene Therapy: AAV-delivered shRNA for long-term tau reduction
The MAPT gene produces six tau isoforms through alternative splicing, and ASO design can be tailored to target specific isoforms. This isoform-specific targeting represents a sophisticated approach to treating different tauopathies.
The six tau isoforms arise from alternative splicing of exons 2, 3, and 10 in the MAPT gene:
- 3-repeat (3R) tau: Exon 10 excluded (exon 2 and 3 may be included or excluded)
- 4-repeat (4R) tau: Exon 10 included (exon 2 and 3 may be included or excluded)
| Isoform |
Exon 2 |
Exon 3 |
Exon 10 |
Repeats |
Length (aa) |
| 0N3R |
- |
- |
- |
3 |
352 |
| 1N3R |
+ |
- |
- |
3 |
379 |
| 2N3R |
+ |
+ |
- |
3 |
410 |
| 0N4R |
- |
- |
+ |
4 |
383 |
| 1N4R |
+ |
- |
+ |
4 |
410 |
| 2N4R |
+ |
+ |
+ |
4 |
441 |
1. Total MAPT Knockdown:
- Targets all six tau isoforms
- Maximum tau reduction (50-60% observed with BIIB080)
- Concerns about tau loss-of-function effects on microtubule function
- Non-human primate studies support safety at therapeutic doses
2. 4R-Selective Targeting:
- 4R tau isoforms are elevated in PSP, CBD, and other 4R-tauopathies
- ASOs can be designed to preferentially reduce 4R isoforms by targeting exon 10
- May preserve 3R tau function for normal neuronal physiology
- Particularly relevant for pure tauopathies without amyloid co-pathology
3. Exon-Specific Targeting:
- Exon 10 splicing produces 4R tau (3 repeats vs 4 repeats)
- ASOs can modulate exon 10 inclusion by targeting splicing regulatory elements
- Therapeutic potential for 4R-tauopathies like PSP and CBD
- Requires careful design to avoid off-target splicing effects
- BIIB080 reduces total tau (all isoforms) — suitable for AD where both 3R and 4R are pathological
- Isoform-selective ASOs in development for specific tauopathies (PSP, CBD)
- Need to balance efficacy with safety — partial reduction may be optimal
- Biomarker development to monitor isoform-specific effects (CSF 3R/4R tau assays)
¶ Safety and Long-Term Effects
Tau is essential for microtubule stabilization in neurons, raising concerns about complete knockout:
- Physiological Function: Tau binds to microtubules and promotes their assembly
- Axonal Transport: Tau facilitates vesicle transport along microtubules
- Synaptic Function: Tau is involved in synaptic plasticity
- Complete Knockout: Mouse tau knockout shows minimal phenotype, but human data limited
Key Finding: ASOs achieve partial reduction (50-60%), not complete knockout, which may be sufficient for therapeutic benefit while preserving essential functions.
Preclinical toxicology in non-human primates supports the safety of tau ASOs:
- Dose-Range Findings: No significant adverse effects at therapeutic doses
- Tau Reduction: Demonstrated dose-dependent CSF tau lowering
- Motor Function: No observable deficits in primate studies
- Histopathology: No relevant CNS pathology at dose levels
From BIIB080 Phase I and I/II trials:
- Injection Site Reactions: Occurred in some patients (IT administration)
- CSF Protein: Transient elevation in some participants
- Neuroinflammation: No significant increase in inflammatory markers
- Liver Enzymes: Mild elevations, reversible upon discontinuation
- AEs Leading to Discontinuation: Low rate (<5%)
- Chronic Dosing: Monthly dosing for up to 12 months showed acceptable safety
- Tau Recovery: Upon discontinuation, CSF tau levels return to baseline
- Immune Response: No anti-drug antibodies detected
- Cognitive Effects: No negative cognitive outcomes in treated patients
Tau ASO development leveraged multiple preclinical models:
Transgenic Mouse Models:
- P301S mice: Express human mutant tau (P301S), develop NFT pathology
- rTg4518 mice: Inducible mutant tau expression, rapid progression
- MAPT knockout mice: For safety assessment of tau reduction
Key Findings:
- ASO treatment reduced CSF and brain tau by 40-80%
- Improved behavioral outcomes in some studies
- Reduced tau pathology markers (AT8, AT100, Gallyas)
- No adverse effects on motor function at therapeutic doses
Translating preclinical biomarker findings to clinical setting:
| Preclinical Marker |
Clinical Correlate |
Status |
| Brain tau (IHC) |
Tau PET |
Validated |
| CSF total tau |
CSF t-tau |
Validated |
| CSF p-tau181/217 |
CSF p-tau181/217 |
Validated |
| Brain AT8 signal |
CSF p-tau |
Partial |
| Motor behavior |
Clinical exams |
Variable |
¶ ASO Chemistry and Delivery
Modern ASOs employ sophisticated chemistry for CNS delivery:
Phosphorothioate (PS) Backbone:
- Replaces non-bridging oxygen with sulfur
- Enhances nuclease resistance
- Improves protein binding (cellular uptake)
2'-O-Methyl (2'-OMe) or 2'-O-Methoxyethyl (2'-MOE):
- 2'-ribose modifications
- Enhanced affinity for target RNA
- Reduced immunostimulation
Locked Nucleic Acid (LNA):
- Constrained nucleotide structure
- High binding affinity
- Improved specificity
Gapmer Design:
- Central DNA "gap" flanked by modified nucleotides
- Optimizes RNase H1 recruitment
- Balances stability and activity
Intrathecal (IT) Administration:
- Lumbar puncture delivery to cerebrospinal fluid
- BIIB080 uses this route
- Bypasses BBB for CNS exposure
Convection-Enhanced Delivery (CED):
- Direct brain infusion under pressure
- Better distribution than IT
- Being explored for next-generation ASOs
AAV-Mediated shRNA:
- AAV vectors deliver shRNA expression cassettes
- Long-term tau reduction from single dose
- Preclinical development
| Parameter |
Intrathecal |
IV |
AAV |
| CNS Exposure |
High |
Low |
High |
| Onset |
Weeks |
N/A |
Months |
| Duration |
Months |
N/A |
Years |
| Patient Burden |
Moderate |
Low |
Low |
RNase H1 is critical for ASO-mediated mRNA degradation:
¶ Structure and Function
- RNase H1 recognizes DNA-RNA hybrids
- Cleaves the RNA strand endonucleolytically
- Requires a minimum 5-nucleotide DNA "gap" in the hybrid
- Expressed in CNS neurons and glia
- Gapmer Length: 5-10 nucleotides optimal
- Positioning: Central DNA region for RNase H1 binding
- Flanking: 2'-modified nucleotides for stability
- Sequence: Target conserved regions of MAPT mRNA
- RNase H1 may cleave unintended RNA pairs
- Computational design reduces off-target risk
- Chemical modifications improve specificity
¶ Comparison: ASO vs Antibody vs Small Molecule
| Feature |
ASO (BIIB080) |
Antibody (E2814) |
Small Molecule (LY3372689) |
| Target |
MAPT mRNA |
Tau protein |
O-GlcNAc hydrolase |
| Mechanism |
Reduce production |
Clear existing |
Increase O-GlcNAcylation |
| Route |
Intrathecal |
IV |
Oral |
| Dosing |
Monthly |
Monthly |
Daily |
| Distribution |
CNS-wide |
Limited by BBB |
CNS-penetrant |
| Isoform Selectivity |
All isoforms |
Epitope-dependent |
All isoforms |
| Phase |
Phase II |
Phase III |
Phase II |
- Early AD (MCI or mild dementia)
- Elevated tau markers (PET or CSF)
- Genetic forms (PSEN1, PSEN2, APP) for DIAN-TU
Primary:
- Safety and tolerability
- CSF total tau and p-tau
Secondary:
- Cognitive measures (CDR-SB, ADAS-Cog)
- Tau PET imaging
- Plasma biomarkers
- CSF tau reduction correlates with target engagement
- May predict clinical outcomes
- Surrogate endpoint for disease modification
- RNAi-Based Therapies:
- siRNA and shRNA approaches
- AAV-delivered gene silencing
- CRISPR-Based Editing:
- Inactivate MAPT gene
- Allele-specific targeting (for mutations)
- Small Molecule Splicing Modulators:
- Modulate exon 10 splicing
- Reduce 4R tau selectively
- ASO + amyloid antibody (e.g., lecanemab)
- ASO + tau antibody
- ASO + OGA inhibitor
This approach represents a complementary strategy to antibody-based immunotherapy, targeting tau at its source rather than clearing already-produced protein.